Literature DB >> 24976972

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): a randomized, double-blind, phase III trial.

Michael DeGregorio1, Lin Soe1, Michael Wolf1.   

Abstract

Entities:  

Year:  2014        PMID： 24976972      PMCID： PMC4073360          DOI： 10.3978/j.issn.2072-1439.2014.05.15

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  11 in total

1.  Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken Up by dendritic cells.

Authors:  E M Hiltbold; M D Alter; P Ciborowski; O J Finn
Journal:  Cell Immunol       Date:  1999-06-15       Impact factor: 4.868

2.  Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

Authors:  Charles Butts; Mark A Socinski; Paul L Mitchell; Nick Thatcher; Libor Havel; Maciej Krzakowski; Sergiusz Nawrocki; Tudor-Eliade Ciuleanu; Lionel Bosquée; José Manuel Trigo; Alexander Spira; Lise Tremblay; Jan Nyman; Rodryg Ramlau; Gun Wickart-Johansson; Peter Ellis; Oleg Gladkov; José Rodrigues Pereira; Wilfried Ernst Erich Eberhardt; Christoph Helwig; Andreas Schröder; Frances A Shepherd
Journal:  Lancet Oncol       Date:  2013-12-09       Impact factor: 41.316

Review 3.  Lung cancer vaccines: current status and future prospects.

Authors:  Charmaine A Ramlogan-Steel; Jason C Steel; John C Morris
Journal:  Transl Lung Cancer Res       Date:  2014-02

Review 4.  Impact of glycans on T-cell tolerance to glycosylated self-antigens.

Authors:  Anthony W Purcell; Ian R van Driel; Paul A Gleeson
Journal:  Immunol Cell Biol       Date:  2008-07-15       Impact factor: 5.126

5.  Antitumor effects of cisplatin combined with tecemotide immunotherapy in a human MUC1 transgenic lung cancer mouse model.

Authors:  Chiao-Jung Kao; Gregory T Wurz; Arta M Monjazeb; Daniel P Vang; Timothy B Cadman; Stephen M Griffey; Michael Wolf; Michael W DeGregorio
Journal:  Cancer Immunol Res       Date:  2014-03-10       Impact factor: 11.151

6.  PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.

Authors:  Julien Fourcade; Zhaojun Sun; Ornella Pagliano; Joe-Marc Chauvin; Cindy Sander; Bratislav Janjic; Ahmad A Tarhini; Hussein A Tawbi; John M Kirkwood; Stergios Moschos; Hong Wang; Philippe Guillaume; Immanuel F Luescher; Arthur Krieg; Ana C Anderson; Vijay K Kuchroo; Hassane M Zarour
Journal:  Cancer Res       Date:  2013-12-16       Impact factor: 12.701

Review 7.  Immunogenic and tolerogenic cell death.

Authors:  Douglas R Green; Thomas Ferguson; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2009-05       Impact factor: 53.106

Review 8.  The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era.

Authors:  Zarnie Lwin; Jonathan W Riess; David Gandara
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

9.  Antitumor effects of L-BLP25 antigen-specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model.

Authors:  Gregory T Wurz; Audrey M Gutierrez; Brittany E Greenberg; Daniel P Vang; Stephen M Griffey; Chiao-Jung Kao; Michael Wolf; Michael W DeGregorio
Journal:  J Transl Med       Date:  2013-03-13       Impact factor: 5.531

10.  Clarifying the pharmacodynamics of tecemotide (L-BLP25)-based combination therapy.

Authors:  Chiao-Jung Kao; Gregory T Wurz; Andreas Schröder; Michael Wolf; Michael W Degregorio
Journal:  Oncoimmunology       Date:  2013-09-12       Impact factor: 8.110
View more
  4 in total

Review 1.  Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential.

Authors:  Gregory T Wurz; Chiao-Jung Kao; Michael W DeGregorio
Journal:  Ther Adv Med Oncol       Date:  2016-01       Impact factor: 8.168

Review 2.  Tecemotide: an antigen-specific cancer immunotherapy.

Authors:  Gregory T Wurz; Chiao-Jung Kao; Michael Wolf; Michael W DeGregorio
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 3.  Immunomodulatory Nanosystems.

Authors:  Xiangru Feng; Weiguo Xu; Zhongmin Li; Wantong Song; Jianxun Ding; Xuesi Chen
Journal:  Adv Sci (Weinh)       Date:  2019-06-21       Impact factor: 16.806

Review 4.  An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery.

Authors:  Kailash C Petkar; Suyash M Patil; Sandip S Chavhan; Kan Kaneko; Krutika K Sawant; Nitesh K Kunda; Imran Y Saleem
Journal:  Pharmaceutics       Date:  2021-03-27       Impact factor: 6.321
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.